Red day on Friday for Aldeyra Therapeutics (Updated on July 30, 2021)
Sell candidate since 2021-07-01 Loss -21.31% PDF
The Aldeyra Therapeutics stock price fell by -1.33% on the last day (Friday, 30th Jul 2021) from $9.02 to $8.90. and has now fallen 3 days in a row. During the day the stock fluctuated 3.64% from a day low at $8.78 to a day high of $9.10. The price has fallen in 6 of the last 10 days and is down by -6.51% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -11 thousand shares and in total, 301 thousand shares were bought and sold for approximately $2.68 million.
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.36% during the next 3 months and, with a 90% probability hold a price between $6.36 and $8.23 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
Signals & Forecast
A buy signal was issued from a pivot bottom point on Monday, July 26, 2021, and so far it has risen 3.13%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Aldeyra Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $8.97 and $10.55. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Support, Risk & Stop-loss
Aldeyra Therapeutics finds support from accumulated volume at $8.81 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.32 between high and low, or 3.64%. For the last week, the stock has had a daily average volatility of 5.57%.
Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.
Is Aldeyra Therapeutics stock A Buy?
Aldeyra Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Current score: -2.017
Predicted Opening Price for Aldeyra Therapeutics of Monday, August 2, 2021
The predicted opening price is based on yesterday's movements between high, low, and the closing price.
|Fair opening price August 2, 2021||Current price|
Remember To Visit Our YouTube Channel
On April 28, 2021 "Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell" gave "" rating for ALDX. The price target was changed from $22.00 to $25.00.
Fibonacci Support & Resistance Levels
Accumulated Volume Support & Resistance Levels
Click to get the best stock tips daily for free!
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 95.000+ Happy SubscribersDon't miss out on the runners!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.